← All trials
NCT04750707
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 9, 2021
- Primary completion
- Aug 31, 2024
- Completion date
- Aug 31, 2024
- First posted
- Feb 11, 2021
- Last posted
- Sep 5, 2021
- Enrollment
- 270
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Global Health Uganda LTDLead sponsor
- National Institutes of Health (NIH)Collaborator
- Emory UniversityCollaborator
- Columbia UniversityOverall official - principal investigator
- Columbia UniversityCollaborator
- University of PittsburghCollaborator
- Makerere UniversityOverall official - principal investigator
- Makerere UniversityCollaborator
- Mulago Hospital, UgandaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.